Fractyl Health (GUTS) Stock: Buy, Sell, or Hold?
GUTS - Fractyl Health, Inc. Common Stock
$0.64
0.00 (-0.48%)
▼
5d:
-6.88%
30d:
-8.05%
90d:
-11.59%
WAIT
LOW Confidence
Analysis Updated: Sep 11, 2026 12:00 AM ET
Earnings: Aug 10, 2026
0d
Get Alerted When GUTS Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 MIXED SIGNALS: GUTS shows conflicting indicators. Wait for confirmation before entering.
📊 MIXED SIGNALS: GUTS shows conflicting indicators. Wait for confirmation before entering.
In-depth Analysis How we analyze
Valuation Analysis: GUTS is currently trading at $0.64, which is considered oversold relative to its 30-day fair value range of $0.66 to $0.73.
Technical Outlook: Technically, GUTS is in a downtrend. The price is currently testing key support at $0.63. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: GUTS scores 36/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $5.03 (+686.5%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, GUTS is in a downtrend. The price is currently testing key support at $0.63. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: GUTS scores 36/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $5.03 (+686.5%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
OVERSOLD
Historical Trading Range
$0.66 -
$0.73
Company Quality Score
43/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
57.9%
All Signals
- BULLISH: Price oversold vs 30-day range
- BEARISH: Weak technical setup (36/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 686.5% below Wall St target ($5.03)
- WARNING: Composite score 43/100 in the bottom quintile — this cohort historically lags the market
Trading Range Analysis
30-Day Trading Range
$0.66 -
$0.73
Current vs Trading Range
OVERSOLD
Support & Resistance Levels
Support Level
$0.63
Resistance Level
$0.77
Current Trend
Downtrend
Technical data as of
Sep 11, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-0.93
Wall Street Target
$5.03
(+686.5%)
Revenue Growth (YoY)
-57.1%
Share & Embed Analysis
Last updated: September 13, 2026 11:58 AM ET
Data refreshes hourly during market hours. Next update: 12:58 PM
Data refreshes hourly during market hours. Next update: 12:58 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is GUTS showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
IONS
Ionis Pharmaceuticals Inc |
BUY
26 analysts |
$84 | 50 HOLD |
|
RARE
Ultragenyx |
STRONG BUY
20 analysts |
$27 | 49 HOLD |
|
ACLX
Arcellx Inc |
STRONG BUY
18 analysts |
$113 | 50 HOLD |
|
RCKT
Rocket Pharmaceuticals I… |
STRONG BUY
18 analysts |
$9 | 41 HOLD |
|
LRMR
Larimar Therapeutics Inc |
STRONG BUY
11 analysts |
$14 | 58 HOLD |
